Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

Infratil adds $250m to its billion-dollar asset sale target
Infrastructure

Infratil adds $250m to its billion-dollar asset sale target

Most of the cash will come from sale of mobile tower business Fortysouth.

Kids KiwiSaver mooted to invest in children's future
Finance

Kids KiwiSaver mooted to invest in children's future

Proposed savings programme could accumulate up to $18 billion in 18 years.

Why Bremworth had to ditch its wool-only strategy
Primary Sector

Why Bremworth had to ditch its wool-only strategy

Carpet maker had private talks about the Godfrey Hirst deal after its AGM.

Mainfreight result lifts market as investors eye Infratil update
Markets

Mainfreight result lifts market as investors eye Infratil update

Positive news from the logistics and transport company has buoyed the NZX.

Tom Raynel 12 Nov 2025